Camarillo, California, January 26, 2024 – AskGene Pharma Inc. announces dosing of the first patient at a participating site in China for the Phase III pivotal trial of ASKB589. ASKB589 is a CLDN18.2 targeting antibody that is being tested in combination with CAPOX and a PD-1 inhibitor. This combination therapy is intended for the first-line […]
Camarillo, California, January 18, 2024 – AskGene Pharma Inc. presented encouraging clinical results for ASKB589, an anti-CLDN18.2 antibody, at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO-GI 2024) in San Francisco on January 18-20, 2024. The results were from clinical trial NCT05632939, a Phase Ib/II, two-part, dose escalation and expansion study to evaluate […]
Camarillo, California, October 16, 2023 – AskGene Pharma Inc. announces that the Center for Drug Evaluation (CDE) of the Chinese National Medicinal Product Administration (NMPA) has granted clearance for the initiation of a Phase III clinical trial to evaluate the efficacy and safety of ASKB589 (anti-CLDN18.2 monoclonal antibody) in combination with CAPOX (capecitabine and oxaliplatin) […]
Camarillo, California, August 21, 2023 – AskGene Pharma Inc. is pleased to announce that the first patient has been dosed at Columbia University Irving Medical Center in New York City in the phase I clinical trial of ASKG915. The study is an open label, multi-regional phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics […]
Camarillo, California, June 16, 2023 – AskGene Pharma Inc. today gave an oral presentation at the 15th International Gastric Cancer Congress (IGCC 2023) in Yokohama, Japan of the latest clinical results from NCT04632108 for ASKB589, an anti-CLDN18.2 antibody, for the treatment of solid tumors. Presentation Details NCT04632108 is a first-in-human study evaluating the safety, tolerability, […]
Camarillo, California, June 2, 2023 – AskGene Pharma Inc. is pleased to announce its participation in the prestigious 15th International Gastric Cancer Congress (IGCC 2023), scheduled to take place on June 14-17, 2023 in Yokohama, Japan. At the conference, AskGene will give an oral presentation on the latest clinical results of NCT04632108 for ASKB589, an […]
Camarillo, California, January 24, 2023 – AskGene Pharma Inc. presented encouraging clinical results for ASKB589, an anti-CLDN18.2 antibody, at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO-GI 2023) in San Francisco on January 19-21, 2023. The results were from clinical trial NCT04632108, a Phase I/II, two-part, dose escalation and expansion study to evaluate […]
Camarillo, California, December 30th, 2022 – AskGene Pharma Inc. is pleased to announce that the first patient completed their first dose (Cycle 1, Day 1) in the phase I clinical trial of ASKG315 in Shanghai, China. The study is an open label, multicenter phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of ASKG315 […]
Camarillo, California, December 30th, 2022 – AskGene Pharma Inc. is pleased to announce that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of ASKG915, a novel and proprietary anti-PD-1-IL-15 prodrug fusion molecule for the treatment of cancer. Under this IND, AskGene will soon […]
Camarillo, California, November 21st, 2022 – AskGene Pharma Inc. is pleased to announce the submission of an Investigational New Drug (IND) application for ASKG915 to the United States Food and Drug Administration (FDA). ASKG915 is a recombinant human anti-PD-1 monoclonal antibody and IL-15 prodrug fusion protein for oncology indications. Jian-Feng (Jeff) Lu, Ph.D., CEO of […]